I would keep NHS criteria and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
NHS criteria and how they are applied in practice posts 31–43
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Collapsed as off-topic by two members at trust level 3 or above
I read post #29 twice before replying, because I had assumed the opposite.
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
Seconded. It reads as careful rather than confident, which is the right register.
Coming back to post #33, because the follow-up matters more than the original answer.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
I have written this out at length because the short version keeps being misread.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Genuinely open to being wrong about this one.
The thing about NHS criteria that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Everything in post #37 holds. The case it does not cover is the one I have.
The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not.
Worth one more sentence than it usually gets.
On NHS criteria: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. Asking about Pharmacy supply on behalf of the…
|
+46 | 53 | 14k | 12mo |
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated June 2026, because everything in this category expires. The…
|
2 | 5.8k | 15mo | |
|
Pharmacy supply in the UK and the questions you will be asked
On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. Asking about pharmacy supply on behalf of the question I keep seeing asked…
|
+95 | 105 | 1.3k | 4mo |
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Asking about MHRA statements directly, because I have read four threads on it and each…
|
2 | 44k | 22mo |
Related topics — sharing the tags NHS, cost per milligram, personal import
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Eu-wide position versus national implementation: what I expected, what I…
|
+22 | 29 | 356 | 11mo |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Asking about Language barriers in accessing on behalf of…
|
+131 | 148 | 28k | 5mo |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. I have spent a fortnight trying to pin personal import allowances down and I want to set out where I…
|
+5 | 9 | 3.2k | 7mo |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting a stated criterion rather than an outcome,…
|
+37 | 42 | 2.1k | 1d |
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |